R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News Case builds for Biogen, Stoke's Dravet syndrome drug Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face